PATH241213C15000
- 0.01
- -0.02-66.67%
UiPath Newsroom
UiPath Initiated at Sell by UBS
UiPath Analyst Ratings
UBS Initiates UiPath(PATH.US) With Sell Rating, Announces Target Price $14
A Quick Look at Today's Ratings for UiPath(PATH.US), With a Forecast Between $15 to $18
UiPath Price Target Raised to $16.00/Share From $15.00 by Barclays
UiPath Price Target Raised to $16.00/Share From $15.00 by Morgan Stanley
UiPath Price Target Raised to $16.00/Share From $15.00 by BMO Capital
UiPath Price Target Maintained With a $16.00/Share by RBC Capital
UiPath Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on UiPath, Raises Price Target to $18
A Quick Look at Today's Ratings for UiPath(PATH.US), With a Forecast Between $16 to $19
UiPath's Growth Potential and Favorable Valuation Supports Buy Rating
UiPath's Modest ARR Growth and Challenges: Hold Rating Maintained Amid Stagnant Customer Acquisition and Execution Uncertainties
UiPath Analyst Ratings
Analysts Conflicted on These Technology Names: UiPath (PATH), Apple (AAPL) and Cricut Inc (CRCT)
UiPath's Steady Performance and Operational Improvements Lead to Hold Rating Amid Uncertain Competitive Landscape
UiPath (PATH) Q3 Pre-Earnings: Analysts Forecast 42% Decline in Earnings
UiPath (PATH) Receives a Rating Update From a Top Analyst
Scotiabank Maintains UiPath(PATH.US) With Hold Rating, Maintains Target Price $15
CCORF Maintains UiPath(PATH.US) With Buy Rating, Maintains Target Price $19